Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to Tarsus Pharmaceuticals' second quarter 2026 financial results conference call and announcement to acquire Alkias Pharmaceuticals. As a reminder, this call is being recorded and all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. At this time, I would like to turn the call over to Sarah Knives, Investor Relations, to lead off the call. Thank you. Before we begin, I encourage everyone to visit the Investors section of the TARCIS website to view the press releases issued today and related materials we will be discussing today. Joining me on the call are Bobak Azamian, our Chief Executive Officer and Chairman, Mira Clates, our Interim Chief Commercial Officer, Seshadri Neervannan, our Chief Operating Officer, and Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer. and joining us for Q&A is Dr. Liz Yeu, our Chief Medical Officer. I'd like to draw your attention to slide three, which contains our forward-looking statements. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional details. With that, I'll turn the call over to Bobby. Hello, and thank you for joining us. Today is an important day for Tarsus. We're reporting another exceptional quarter for Extenvi in announcing the acquisition of Alceus Pharmaceuticals and Gilder Retinol, or ALK001, a late-stage investigational therapy for Stargardt disease. When we launched Xtemvi, we believed deminexliferitis, or DB, was one of the largest diseases in eye care, h...